Perfusion Systems Market Report 2025

The perfusion systems market size has grown strongly in recent years. It will grow from $1.33 billion in 2024 to $1.46 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to the foundational research in perfusion science, the introduction of hypothermia techniques, the inception of cardiopulmonary bypass, and early heart-lung machine development.

The perfusion systems market size is expected to see rapid growth in the next few years. It will grow to $2.15 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to a focus on patient outcomes, a rise in cardiovascular surgeries, expansion of minimally invasive procedures, increased ECMO usage, global healthcare infrastructure development, and growing geriatric population. Major trends in the forecast period include portable and compact designs, automation and robotics integration, remote monitoring and telemedicine, modular and customizable platforms, advanced data analytics, and AI.

The surge in organ transplants stands as a significant driving force behind the anticipated growth of the perfusion systems market. Organ transplants involve the surgical transfer of diseased or damaged organs from donors to recipients facing organ failure or disease. Perfusion systems play a vital role in this process by preserving and transporting organs, ensuring their viability during transplantation. Notably, data from the Organ Procurement and Transplantation Network in January 2021 indicated a 5.9% increase in organ transplants in the US, totaling 41,354 procedures, compared to the previous year. This uptick underscores the escalating demand driving the perfusion systems market due to the rising need for successful organ transplants.

The growing aging population is anticipated to drive the expansion of the perfusion systems market in the coming years. An aging population is characterized by a larger percentage of individuals aged 65 and older, which often correlates with a rise in age-related diseases that can lead to organ failure. Perfusion systems play a crucial role in organ transplantation by preserving and transporting organs from donors to recipients. These systems are designed to maintain organ viability outside the human body, thereby enhancing the likelihood of successful transplants. For example, the World Health Organization, a specialized agency of the United Nations focused on global public health, projects that by 2030, approximately 1 in 6 people worldwide will be 60 years or older. Additionally, the global population of individuals aged 60 and above is expected to double to 2.1 billion by 2050. Consequently, the increasing aging population is propelling the growth of the perfusion systems market.

Product innovation emerges as a prominent trend within the perfusion systems market. Leading market players are channeling efforts into developing innovative solutions to fortify their market positions. An instance is LivaNova's February 2023 launch of the Essenz perfusion system in Europe. This system, known for its compact, modular, and portable design, is a cardiopulmonary bypass (CPB) system tailored for cardiac surgeries. Its modularity allows customization for diverse patient needs and surgical procedures, facilitating its versatility across clinical settings.

Major companies in the perfusion systems market are focusing on developing innovative products to enhance clinical efficiency and patient care, particularly during cardiopulmonary bypass (CPB) procedures. A notable example is the Essenz Patient Monitor, which features a centralized display that continuously shows critical patient parameters, enabling tailored management strategies. In April 2022, LivaNova PLC, a UK-based medical technology and innovation company, announced the regulatory approvals and targeted commercial launch of the Essenz Patient Monitor. This advanced monitoring system adopts a patient-centered approach to improve clinical efficiency and care quality during CPB procedures. It received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Mark, leading to its initial launch in select hospitals across the U.S. and Europe that participated in the user-centric design program. The Essenz Patient Monitor enhances decision-making for perfusionists throughout the CPB procedure and is fully compatible with the LivaNova S5 heart-lung machine. Such innovations reflect a broader trend toward improving outcomes in cardiac surgeries through advanced monitoring technologies.

In December 2022, Merck & Co Inc., a prominent US-based pharmaceutical company, finalized the acquisition of Erbi Biosystems Inc. for an undisclosed sum. This strategic acquisition aims to facilitate the development of scalable cell-based perfusion bioreactor processes, initiating from as little as 2 ml. This move significantly strengthens Merck's upstream portfolio concerning therapeutic proteins. Among Merck's key growth drivers - referred to as its "Big 3," alongside the Life Science Services business unit, the Process Solutions business unit holds pivotal significance. The integration of Erbi Biosystems aligns with Merck's commitment to driving innovation within this specific business unit. Notably, Erbi Biosystems Inc. is a biotechnology tools company based in the United States.

Major companies operating in the perfusion systems market include Getinge AB, Medtronic plc, LivaNova PLC, Terumo Corporation, Lifeline Scientific Inc., XVIVO Perfusion AB, Repligen Corporation, Spectrum Laboratories Inc., Merck KGaA, Harvard Bioscience Inc., ALA Scientific Instruments Inc., XENIOS AG, Siemens Healthcare Private Limited Shimadzu Corporation, GENERAL ELECTRIC COMPANY, Organ Assist Products B.V., Hitachi Ltd., Bioptechs Inc., Cytiva Company, Sorin Group, Organ Recovery Systems Inc., TransMedics Inc., Paragonix Technologies Inc., Bridge to Life (Europe) Ltd., OrganOx Limited, Preservation Solutions Inc.

North America was the largest region in the perfusion systems market in 2024. The regions covered in the perfusion systems market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the perfusion systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Perfusion systems encompass vital medical devices employed to sustain blood circulation and oxygenation in patients during surgical procedures necessitating a temporary pause in the heart's normal function. Primarily utilized in cardiac surgeries, organ transplants, and other procedures requiring temporary organ function support, these systems play a critical role in maintaining physiological stability.

They come in various types, including cardiopulmonary perfusion systems, extracorporeal membrane oxygenation (ECMO), isolated organ perfusion systems, and specialized variations. Cardiopulmonary perfusion systems specifically substitute the heart and lung functions temporarily during cardiac surgeries. These systems cater to diverse organs such as the heart, lungs, kidneys, liver, and others, employing techniques such as hypothermic and normothermic approaches. Their applications span across different healthcare settings, including hospitals, clinics, ambulatory surgical centers, and various other medical facilities.

The perfusion systems market research report is one of a series of new reports that provides perfusion systems market statistics, including perfusion systems industry global market size, regional shares, competitors with a perfusion systems market share, detailed perfusion systems market segments, market trends and opportunities, and any further data you may need to thrive in the perfusion systems industry. This perfusion systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The perfusion systems market consists of revenues earned by entities by providing organ transplantation service, blood management services, cell isolation care, cardiac and respiratory disorders surgery services. The market value includes the value of related goods sold by the service provider or included within the service offering. The perfusion systems market also includes sales of oxygenators, tubing, and filters equipment which are used in providing perfusion systems related services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.